All payments made in the preview are in test mode. Read more
RUORUO FoundationResearch Use Only Standards

Reference

Peptide database

Structured, citation-backed entries written for laboratory handling and legal literacy. No entry contains dosing information, protocols for human use, or therapeutic claims.

6 of 6 entries

BPC-157

Synthetic peptide fragment - research use only

Also indexed as: Body Protection Compound 157, PL 14736

Structure
Pentadecapeptide (15 amino acids) derived from a human gastric protein fragment.
Research areas
Tissue repair models · Gastrointestinal injury models · Angiogenesis assays
Handling & storage
Supplied as lyophilized powder. Reconstitution in bacteriostatic or sterile water is typical in laboratory protocols; store lyophilized material at -20 °C and reconstituted material refrigerated and protected from light.
Documented hazards
Purity, endotoxin load, and residual solvents vary widely between suppliers. Unverified material may contain incorrect sequences or contaminants.
Regulatory status
Not approved by the FDA for any use. Placed on the FDA's list of substances nominated for the 503A/503B bulk compounding categories and not permitted for compounding as of the agency's Category 2 designation. Prohibited in sport under the WADA S0 class.

Literature

TB-500 (Thymosin β4 fragment)

Synthetic peptide fragment - research use only

Also indexed as: Thymosin Beta-4 fragment, Tβ4 17-23

Structure
Seven-residue actin-binding fragment of the 43-residue protein thymosin β4.
Research areas
Cell migration assays · Wound-healing models · Cardiac injury models
Handling & storage
Lyophilized powder; sensitive to repeated freeze-thaw cycles. Aliquot after reconstitution to preserve integrity.
Documented hazards
Fragment products are frequently mislabeled as full-length thymosin β4. Sequence verification by mass spectrometry is the only reliable check.
Regulatory status
No FDA approval. Prohibited in sport under WADA S2. Interstate sale for human use is unlawful.

Literature

Semaglutide

Approved drug substance - RUO material is not pharmaceutical grade

Also indexed as: GLP-1 receptor agonist

Structure
Acylated 31-residue GLP-1 analogue with an AIB substitution at position 8.
Research areas
Incretin signaling · Metabolic models · Receptor binding assays
Handling & storage
Highly sensitive to agitation and temperature. Reference standards are sourced from pharmacopeial suppliers with certificates of analysis.
Documented hazards
Because an approved drug product exists, RUO-labeled semaglutide is a frequent vector for counterfeit and mislabeled material. Reported analyses have found incorrect content and unidentified impurities.
Regulatory status
Approved as a finished drug product under specific NDAs. Bulk RUO material may not be compounded or distributed for human use; the FDA has issued warnings regarding compounded and counterfeit semaglutide.

Literature

Ipamorelin

Synthetic peptide - research use only

Also indexed as: NNC 26-0161

Structure
Pentapeptide growth hormone secretagogue, ghrelin receptor (GHS-R1a) agonist.
Research areas
GHS-R1a receptor pharmacology · Endocrine signaling models
Handling & storage
Lyophilized; stable at -20 °C. Avoid prolonged exposure to ambient temperature.
Documented hazards
Growth hormone secretagogues are commonly adulterated or substituted with lower-cost peptides.
Regulatory status
No FDA approval; discontinued in clinical development. Prohibited in sport under WADA S2.

Literature

GHK-Cu

Cosmetic ingredient / research reagent

Also indexed as: Copper tripeptide-1

Structure
Tripeptide glycyl-L-histidyl-L-lysine complexed with copper(II).
Research areas
Extracellular matrix remodeling · Fibroblast culture studies
Handling & storage
Copper complexes are light- and pH-sensitive. Store dry and protected from light; verify copper content, not just peptide mass.
Documented hazards
Copper overload is a genuine toxicological concern in cell and animal models.
Regulatory status
Used as a cosmetic ingredient under different regulatory pathways than drugs. RUO material is not cosmetic-grade unless documented as such.

Literature

CJC-1295

Synthetic peptide - research use only

Also indexed as: Modified GRF (1-29), DAC:GRF

Structure
Growth hormone releasing hormone analogue; sold with and without a drug affinity complex (DAC).
Research areas
GHRH receptor studies · Pulsatile hormone release models
Handling & storage
The DAC and non-DAC forms are chemically distinct and are routinely confused in the supply chain. Confirm which form a certificate of analysis describes.
Documented hazards
Historic safety concerns in early clinical work; unverified material carries additional impurity risk.
Regulatory status
No FDA approval. Prohibited in sport under WADA S2.

Literature